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Background and purpose: P2Y receptors evoke Ca2+ signals in vascular smooth muscle cells and regulate contraction and
proliferation, but the roles of the different P2Y receptor subtypes are incompletely resolved.
Experimental approach: Quantitative PCR was used to deﬁne expression of mRNA encoding P2Y receptor subtypes in freshly
isolated and cultured rat aortic smooth muscle cells (ASMC). Fluorescent indicators in combination with selective ligands were
used to measure the changes in cytosolic free [Ca2+] in cultured ASMC evoked by each P2Y receptor subtype.
Key results: The mRNA for all rat P2Y receptor subtypes are expressed at various levels in cultured ASMC. Four P2Y receptor
subtypes (P2Y1, P2Y2, P2Y4 and P2Y6) evoke Ca2+ signals that require activation of phospholipase C and comprise both release
of Ca2+ from stores and Ca2+ entry across the plasma membrane.
Conclusions and implications: Combining analysis of P2Y receptor expression with functional analyses using selective
agonists and antagonists, we isolated the Ca2+ signals evoked in ASMC by activation of P2Y1, P2Y2, P2Y4 and P2Y6 receptors.
British Journal of Pharmacology (2010) 160, 1953–1962; doi:10.1111/j.1476-5381.2010.00763.x
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Abbreviations: [Ca2+]i, cytosolic free Ca2+ concentration; 2′-amino-UTP, 2′-amino-2′-deoxyuridine-5′-triphosphate; 2′-azido-
UTP, 2′-azido-2′-deoxyuridine-5′-triphosphate; 2-MeSADP, 2-methylthio-adenosine-5′-diphosphate; 2-thio-
UTP, 2-thio-uridine-5′-triphosphate; ab-meATP, ab-methylene-adenosine-5′-triphosphate; ASMC, aortic
smooth muscle cell; DMEM, Dulbecco’s modiﬁed Eagle’s medium; HBSS, Hank’s balanced salt solution;
MRS2211, 2-[(2-chloro-5-nitrophenyl)azo]-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridinecarbox
aldehyde; MRS2279, 2-chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosione-3′,5′-bisphosphate;
MRS2365, (N)-methanocarba-2-MeSADP; MRS2395, 2,2-dimethyl-propionic acid 3-(2-chloro-6-methyla
minopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester; MRS2578, N,N″-1,4-butanediylbis [N′-(3-
isothiocyanatophenyl)thio] urea; MRS2690, diphosphoric acid 1-a-D-glucopyranosyl ester 2-[(4′-
methylthio)uridin-5″-yl] ester; PBS, phosphate-buffered saline; U73122, 1-[6-[[(17b)-3-methoxyestra-1,3,5
(10)-trien-17-yl] amino] hexyl]-1H-pyrrole-2,5-dione; U73343, 1-[6-[((17b)-3-methoxyestra-1,3,5 (10)-trien-
17-yl)amino] hexyl]-2,5-pyrrolidinedione; UDP-Glc, uridine-5′-diphospho-a-D-glucose
Introduction
P2Y receptors comprise a family of G protein-coupled recep-
tors that are activated by adenine and uridine nucleotides,
many of which evoke increases in cytosolic Ca
2+ concentra-
tion (Abbracchio et al., 2006) (Figure 1). The seven P2Y recep-
tor subtypes known to be expressed in rats have overlapping
ligand-recognition properties; they differ in the G proteins
that they preferentially activate, and in whether they regulate
phospholipase C, adenylyl cyclase or both. This complexity
and the limited range of subtype-selective antagonists make it
difﬁcult to discriminate the role of each P2Y receptor subtype
in native tissues. In vascular smooth muscle, for example,
many functional responses are regulated by the Ca
2+ signals
evoked by purinoceptors (Erlinge, 1998; Burnstock, 2002;
Hou et al., 2002; Vial and Evans, 2002). These receptors are
activated by extracellular nucleotides released by many differ-
ent cells, including activated platelets, and they can be further
metabolized by extracellular nucleotidases (Abbracchio et al.,
2006). The Ca
2+ signals regulate contraction (Horowitz et al.,
1996) and thereby contribute to control of blood pressure.
They also regulate proliferation and are thereby important in
mediating responses to vascular injury during restenosis
(Inoue and Node, 2009) and atherosclerosis (Owens et al.,
2004). Analyses of the roles of speciﬁc P2Y receptors in
evoking Ca
2+ signals in vascular smooth muscle has, however,
been hampered by the lack of selective ligands (Harper et al.,
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to resolve the roles of each P2Y receptor subtype in mediating
the Ca
2+ signals evoked by nucleotides and so perhaps to
identify receptors that might selectively contribute to control
of contractility or proliferation.
In culture, vascular smooth muscle cells develop a prolif-
erative phenotype that is more reminiscent of cells contrib-
uting to vascular remodelling than the contractile phenotype
of fully differentiated cells (Schwartz et al., 1986). Although
cultured cells are not contractile, they continue to express
several vascular smooth muscle-speciﬁc proteins, including
smooth muscle a-actin (Chamley-Campbell et al., 1979), and
in common with intact tissues they express a variety of func-
tional purinoceptors (Erlinge, 1998; Hou et al., 2002; Vial and
Evans, 2002; Burnstock, 2009). Cultured vascular smooth
muscle cells are thus a useful model for the proliferative state
and they afford opportunities for quantitative analysis of the
Ca
2+ signals evoked by different purinoceptors.
Methods
Isolation and culture of rat aortic smooth muscle cells
All animal care and experimental procedures complied with
UK Home Ofﬁce policy. Smooth muscle cells were isolated
from the aortas of adult male Wistar rats (250–300 g) by
enzymatic digestion (Orallo, 1997). Brieﬂy, rats were
humanely killed by cervical dislocation. The aorta was iso-
lated under sterile conditions in Hank’s balanced salt solution
(HBSS) supplemented with penicillin (100 U·mL
-1) and strep-
tomycin (100 mg·mL
-1), and cleared of adhering fat, connec-
tive tissue and the inner endothelial layer. After the ﬁrst
digestion (37°C, 12 min) in HBSS supplemented with antibi-
otics and collagenase B (0.015 units·mL
-1), the adventitia were
removed. After a second digestion (37°C, 90 min) in HBSS
containing antibiotics, collagenase B (0.075 U·mL
-1) and
elastase (8 U·mL
-1), single cells were dispersed by trituration
with a sterile Pasteur pipette. The cells were washed with
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (650 g, 5 min),
resuspended in DMEM with antibiotics and fetal calf serum
(10%) and grown at 37°C in a humidiﬁed atmosphere of 95%
air and 5% CO2. The aortic smooth muscle cells (ASMC) were
either passaged or frozen when they reached conﬂuence. Cells
were used between passages 2 and 8, throughout which they
retained the appearance of smooth muscle cells and the char-
acteristic ‘hill and valley’ growth pattern (Chamley-Campbell
et al., 1979) and, assessed by immunostaining, they expressed
smooth muscle a-actin (Figure 2A and B).
Quantitative PCR
Conﬂuent cultures of cells in 96-well plates were lysed with
Fastlane cell cDNA kit (50 mL·well
-1, Qiagen, Crawley, West
Sussex, UK), and cDNA was then synthesized from the extract
(4 mL) in a ﬁnal volume of 20 mL and diluted 10-fold in water.
For quantitative PCR, each reaction included primers speciﬁc
for P2Y receptor subtypes or, for calibration, primers for
b-actin. The primers used are listed in Table S1. Each reaction
(15 mL) included cDNA (0.5 mL), P2Y receptor-speciﬁc primers
(Quantitect Primer Assay, Qiagen, 1.5 mL) or b-actin primers
(1.5 mL, 500 nM ﬁnal concentration), and Bioline Sensimix
(Bioline, London, UK, 7.5 mL). For PCR (Rotor-Gene 6000,
Qiagen), an initial denaturation (95°C, 10 min) was followed
by 40 cycles of ampliﬁcation (95°C for 10 s, 60°C for 30 s and
72°C for 20 s), with ﬂuorescence measured at the end of each
cycle. For each PCR, ampliﬁcation efﬁciency (E) was calcu-
lated as 10
m, where m is the average increase in ﬂuorescence
for four cycles after the cycle threshold (CT). Expression levels
relative to the housekeeping product (b-actin) were calculated
from: relative expression = E
-C
T
(P2Y)/E
-C
T
(b-actin). Each QPCR reac-
tion was performed in duplicate with samples from three
different wells. The authenticity of each PCR product was
assessed by melting-curve analysis (72°C for 2 min, then 1°C
steps at 5 s intervals to 99°C). Each reaction produced a single
Figure 1 Selectivity of ligands for the P2Y receptors expressed in rat cultured ASMC. (Abbracchio et al., 2006). The structures of the ligands
are shown in Figure S1. 2′-amino-UTP, 2′-amino-2′-deoxyuridine-5′-triphosphate; 2′-azido-UTP, 2′-azido-2′-deoxyuridine-5′-triphosphate;
2-MeSADP, 2-methylthio-adenosine-5′-diphosphate; 2-thio-UTP, 2-thio-uridine-5′-triphosphate; MRS2211, 2-[(2-chloro-5-nitrophenyl)azo]-5-
hydroxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; MRS2279, 2-chloro-N
6-methyl-(N)-methanocarba-2′-deoxyadeno
sione-3′,5′-bisphosphate; MRS2365, (N)-methanocarba-2-MeSADP; MRS2395, 2,2-dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-
9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester; MRS2578, N,N″-1,4-butanediylbis [N′-(3-isothiocyanatophenyl)thio] urea; UDP-Glc,
uridine-5′-diphospho-a-D-glucose.
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Control reactions in which the template cDNA was omitted
from the PCR reaction, or reverse-transcriptase omitted from
the reverse transcription reaction, failed to produce any spe-
ciﬁc ampliﬁcation products. Similar methods were used for
analyses of cells freshly isolated from aorta (30 mg) immedi-
ately before the second enzyme digestion, as described above.
For these cells, RNA was extracted using an Illustra RNA spin
mini-RNA isolation kit (GE Healthcare, Little Chalfont, Buck-
inghamshire, UK), and cDNA was synthesized using Bioscript
reverse transcriptase (Bioline).
Measurement of [Ca
2+]i in cell populations
Conﬂuent cultures of cells grown in 96-well plates were
loaded with ﬂuo-4 by incubation in HEPES-buffered saline
(HBS) supplemented with probenecid (2.5 mM) and ﬂuo-4
acetoxymethyl ester [4 mM in fresh dimethyl sulphoxide
(DMSO); ﬁnal DMSO concentration, 0.4%]. After 1 h at 20°C,
cells were washed with HBS and after 30 min (to allow com-
plete de-esteriﬁcation of ﬂuo-4AM), they were used for experi-
ments. HBS had the following composition: 135 mM NaCl,
5.9 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 11.5 mM glucose
and 11.6 mM HEPES, pH 7.3, at 20°C. All experiments were
Figure 2 Ca2+ signals evoked by ATP in cultured ASMC. Typical ﬁeld of cultured rat ASMC at passage 5 (A). Field of cells immunostained for
smooth muscle a-actin (B). Ca2+ signals recorded from a population of ﬂuo-4-loaded ASMC stimulated with ATP (100 mM, bar) in the presence
or absence of extracellular Ca2+ (C). Results are means  SEM from three wells on a single plate and are typical of results from three
independent plates. Concentration-dependent effects of ATP on the peak increase in [Ca
2+]i in the presence or absence of extracellular Ca2+,
and on the sustained Ca2+ entry signal (measured 250–300 s after addition of ATP) (D). C denotes control. Peak responses to ATP (100 mM)
with the indicated concentrations of U73122 or U73343 (each added for 5 min before and then during the stimulation) (E). [Ca
2+]i, cytosolic
free Ca2+ concentration; ASMC, aortic smooth muscle cell; HBS, HEPES-buffered saline; U73122, 1-[6-[[(17b)-3-methoxyestra-1,3,5 (10)-trien-
17-yl] amino] hexyl]-1H-pyrrole-2,5-dione; U73343, 1-[6-[((17b)-3-methoxyestra-1,3,5 (10)-trien-17-yl)amino] hexyl]-2,5-pyrrolidinedione.
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2+-free HBS) at 20°C. For
ﬂuorescence measurements, the 96-well plate containing
ﬂuo-4-loaded cells was mounted in a FlexStation III (MDS
Analytical Technologies, Wokingham, Berkshire, UK), which
allows up to three automated additions to each well, while
recording ﬂuorescence (excitation at 485 nm; emission at
525 nm). Six simultaneous readings were taken from each
well at intervals of 1.52 s. At the end of each experiment,
ﬂuorescence of Ca
2+-saturated indicator (Fmax) was determined
for each well by addition of Triton X-100 (0.05%) and CaCl2
(10 mM). Fluorescence from cells containing only Ca
2+-free
indicator (equivalent to background ﬂuorescence because
Ca
2+-free ﬂuo-4 is not ﬂuorescent) was measured in parallel
wells treated with Triton X-100 (0.05%) and BAPTA (10 mM).
This background ﬂuorescence was subtracted from all mea-
surements. The corrected ﬂuorescence (F) was then calibrated
to cytosolic free Ca
2+ concentration ([Ca
2+]i) from: [Ca
2+]i =
KDF/(Fmax - F), where the KD of ﬂuo-4 for Ca
2+ is 345 nM (Gee
et al., 2000).
Immunostaining
Cells grown on poly-L-lysine-coated coverslips under condi-
tions identical to those used for measurements of [Ca
2+]i were
washed twice with phosphate-buffered saline (PBS: 137 mM
NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4 and 1.76 mM KH2PO4,
pH 7.4) and ﬁxed with paraformaldehyde (4%) in PBS for
20 min at 20°C. Cells were then permeabilized with Triton
X-100 (0.1%) in PBS for 5 min. Non-speciﬁc binding was
blocked by incubating with BSA (5%) in PBS for 10 min at
20°C, before staining with a FITC-conjugated monoclonal
antibody to anti-smooth muscle a-actin (1:200) for 2.5 h at
20°C. Cells were then washed three times with PBS, and the
nuclei stained with Hoechst 33258 (1 mg·mL
-1). Coverslips
were mounted in Prolong Gold (Invitrogen, Paisley, Scotland)
and stored at -20°C before confocal imaging.
Statistical analysis
Results are presented as means  SEM from n independent
experiments (n = 3, unless otherwise stated). Statistical com-
parisons used paired or unpaired Student’s t-test, as appropri-
ate, with P < 0.05 considered signiﬁcant (GraphPad Prism,
version 5, La Jolla, CA, USA).
Materials
Collagenase B and hexokinase were from Roche Applied
Science (Burgess Hill, West Sussex, UK). Elastase and FITC-
conjugated a-actin antiserum were from Sigma (Poole, Dorset,
UK). MRS2211 (2-[(2-chloro-5-nitrophenyl)azo]-5-hydroxy-6-
methyl-3-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde),
MRS2279 (2-chloro-N
6-methyl-(N)-methanocarba-2′-
deoxyadenosione-3′,5′-bisphosphate), MRS2365 [(N)-
methanocarba-2-MeSADP], MRS2578 (N,N″-1,4-butanediylbis
[N′-(3-isothiocyanatophenyl)thio] urea), MRS2690
(diphosphoric acid 1-a-D-glucopyranosyl ester 2-[(4′-
methylthio)uridin-5″-yl] ester), 2-MeSADP (2-methylthio-
adenosine-5′-diphosphate) and UDP were from Tocris (Bristol,
Avon, UK). Cell culture materials were from Invitrogen,
except for fetal bovine serum (Sigma). 2′-amino-UTP (2′-
amino-2′-deoxyuridine-5′-triphosphate), 2′-azido-UTP (2′-
azido-2′-deoxyuridine-5′-triphosphate) and 2-thio-UTP
(2-thio-uridine-5′-triphosphate) were from Trilink Biotech-
nologies (San Diego, CA, USA). The structures of the ligands
are shown in Figure S1. Fluo-4AM was from Invitrogen. Per-
tussis toxin was from List Biological Laboratories (Campbell,
CA, USA). Other reagents, including MRS2395 (2,2-dimethyl-
propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-
dimethyl-propionyloxymethyl)-propyl ester), were from
Sigma unless stated otherwise. The nomenclature of receptors
and ligands follows Alexander et al. (2009).
Results
Ca
2+ signals evoked by ATP in rat aortic smooth muscle cells
ATP evoked a concentration-dependent increase in [Ca
2+]i in
populations of rat ASMC. Both the initial peak response and
its sensitivity to ATP were unaffected by removal of extracel-
lular Ca
2+, but a small sustained Ca
2+ signal was abolished in
Ca
2+-free medium (Figure 2C and D; Table 1). There was
Table 1 Ca2+ signals evoked by activation of P2Y receptors
D[Ca
2+]i (nM) pEC50 (h)
Peak Sustained Peak (Ca
2+-free) Peak (with Ca
2+)C a
2+ entry
ATP 248  48 64  20 5.95  0.10 (1.1  0.2) 5.83  0.03 (1.4  0.2) 5.01  0.13 (1.8  0.4)
MRS2365 154  51 8  7 8.56  0.06 (0.9  0.1) 8.68  0.16 (0.8  0.2) 8.11  0.32 (0.7  0.2)
UTP 254  47 67  5 5.39  0.15 (1.1  0.1) 5.23  0.22 (1.0  0.2) 4.64  0.32 (0.7  0.2)
UDP 94  20 25  6 6.16  0.43 (0.6  0.2) 6.45  0.45 (0.6  0.2) 6.83  0.35 (0.7  0.1)
2′-amino-UTP 301  34 84  36 ND 5.58  0.37 (1.1  0.1) 5.40  0.23 (1.1  0.1)
2-thio-UTP 327  42 88  26 ND 5.89  0.29 (1.1  0.3) 5.11 + 0.18 (1.1  0.2)
2′-azido-UTP 142  29 55  20 ND 4.67  0.32 (1.3  0.1) 4.67  0.06 (1.1  0.1)
2-MeSADP 122  30 18  4 ND 7.23  0.53 (0.8  0.1) 5.58  0.16 (1.8  0.7)
The results in the Table show the peak and sustained increase (measured between 250 and 300 s) in [Ca2+]i in populations of cultured ASMC stimulated with the
indicated ligands. pEC50 values with Hill coefﬁcients (h) are shown for the responses in HBS and Ca2+-free HBS, and for the Ca2+ entry.
[Ca2+]i, cytosolic free Ca2+ concentration; 2′-amino-UTP, 2′-amino-2′-deoxyuridine-5′-triphosphate; 2′-azido-UTP, 2′-azido-2′-deoxyuridine-5′-triphosphate;
2-MeSADP, 2-methylthio-adenosine-5′-diphosphate; 2-thio-UTP, 2-thio-uridine-5′-triphosphate; HBS, HEPES-buffered saline; MRS2365, (N)-methanocarba-2-
MeSADP; ND, not determined.
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triphosphate), a selective agonist of P2X1 and P2X3 receptors
(not shown); the former, with P2X7 receptors, predominate in
vascular smooth muscle (North, 2002). The lack of responses
mediated by P2X receptors is consistent with previous studies
indicating that P2X receptors are down-regulated in cultured
vascular smooth muscle cells (Erlinge et al., 1998). The Ca
2+
signals and their sensitivity to ATP were unaffected by treat-
ment of the ATP and cells with an ATP-regenerating system
(2 U·mL
-1, creatine phosphokinase, 1 mM phosphocreatine
and 10 mM LiCl in HBS for 10 min) (Figure S2A). This con-
ﬁrms that the Ca
2+ signals are evoked by ATP rather than by
contaminating ADP. U73122 (1-[6-[[(17b)-3-methoxyestra-
1,3,5 (10)-trien-17-yl] amino] hexyl]-1H-pyrrole-2,5-dione),
an inhibitor of phospholipase C (Bleasdale et al., 1990),
caused a concentration-dependent and complete inhibition
(pIC50 = 5.78  0.07) of the Ca
2+ signals evoked by ATP; the
inactive analogue, U73343 (1-[6-[((17b)-3-methoxyestra-1,3,5
(10)-trien-17-yl)amino] hexyl]-2,5-pyrrolidinedione), had no
effect (Figure 2E). These results demonstrate that activation of
P2Y receptors by ATP in rat ASMC evokes both Ca
2+ release
and Ca
2+ entry via activation of phospholipase C.
Expression of P2Y receptor subtypes in rat aortic smooth
muscle cells
ATP is an agonist of several subtypes of P2Y receptor (Abbrac-
chio et al., 2006) (Figure 1). We therefore used PCR to quan-
tify the transcripts for all known rat P2Y receptor subtypes in
cultures of ASMC before attempting to delineate the subtypes
responsible for ATP-evoked Ca
2+ signals. The results demon-
strate the presence of transcripts for seven different P2Y recep-
tor subtypes, including three for which ATP is an agonist
(Figure 3A). These results establish which P2Y receptors may
be expressed in rat ASMC and thereby dictate our choice of
ligands to resolve, in functional assays, the receptor subtypes
that mediate Ca
2+ signals (Figure 1). Similar analyses of freshly
isolated ASMC established a different pattern of expression
with mRNA for only three P2Y receptors predominating
(P2Y2, P2Y12 and P2Y14) (Figure 3B). It is noteworthy that
the predominant P2Y receptor subtype in cultured ASMC is
P2Y6, which is involved in regulating proliferation (Hou et al.,
2002), whereas P2Y12 is the major subtype in freshly isolated
ASMC (Figure 3). The substantial effects of cell culture on the
expression of mRNA for P2Y6 receptors differ from a previous
study of a more limited range of P2Y receptors, in which
relative levels of expression of the P2Y receptor subtypes were
similar in fresh and cultured ASMC (Erlinge et al., 1998). Here,
we focus on analyses of cultured ASMC because they are more
amenable than primary cells to quantitative analyses of the
Ca
2+ signals evoked by different P2Y receptors.
Some of the P2Y receptor subtypes identiﬁed by PCR analy-
sis are activated by UTP and/or UDP, rather than ATP
(Figure 1). We therefore examined the effects of UTP and UDP
on Ca
2+ signals in ASMC. Responses to UTP were unaffected by
treatment with a regenerating system (as described above)
(Figure S2B), but responses to the highest concentrations of
UDP (>10 mM) were reduced after the UDP was treated (1 h,
37°C) with hexokinase (50 U·mL
-1, pH 7.0 in 0.1 M phosphate
buffer with 6.5 mM MgCl2) and glucose (110 mM) (Figure 4A).
This indicated that the UDP was contaminated with UTP
(Harden et al., 1997; Kumari et al., 2003). We therefore treated
UDP with glucose/hexokinase before all assays. Both UTP and
UDP evoked Ca
2+ release and Ca
2+ entry (Figure 4B and C;
Table 1). These responses, like those to ATP, were abolished by
inhibition of phospholipase C with U73122 (not shown). The
peak increases in [Ca
2+]i were similar for ATP and UTP, but
clearly smaller for UDP (Table 1). The results so far established
that ATP, UTP and UDP, via P2Y receptors, evoked both Ca
2+
release and Ca
2+ entry via their ability to activate phospholi-
pase C in rat cultured ASMC.
Activation of P2Y1 receptors evokes Ca
2+ signals
MRS2365 is a selective full agonist of P2Y1 receptors (Chha-
triwala et al., 2004), while MRS2279 is a selective high-afﬁnity
(KD ~ 8 nM) competitive antagonist (Boyer et al., 2002; Waldo
et al., 2002). MRS2365 evoked concentration-dependent
increases in [Ca
2+]i (pEC50 is shown in Table 1) arising from
both release of Ca
2+ from intracellular stores and Ca
2+ entry
(Figure 5A). Increasing concentrations of MRS2279 caused
rightward parallel shifts in the concentration–effect relation-
ships for the Ca
2+ signals evoked by MRS2365 (Figure 5B). The
pKD of MRS2279 for the receptor through which MRS2365
evokes Ca
2+ signals was 8.16  0.26 (Figure 5C). These results
and the KD for MRS2279 are consistent with expression of
functional P2Y1 receptors in rat cultured ASMC.
2-MeSADP is a full agonist for three of the P2Y receptor
subtypes identiﬁed in ASMC by PCR (P2Y1, P2Y12 and P2Y13)
Figure 3 Expression of P2Y receptor subtypes in aortic smooth muscle cell (ASMC). Quantitative PCR was used to measure relative levels of
mRNA encoding the subtypes of P2Y receptors in either cultures of ASMC (A, passage 3–7) or in freshly isolated ASMC (B). Results, expressed
as percentages of total mRNA encoding P2Y receptors, are means  SEM from three experiments, each performed in duplicate.
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increase in [Ca
2+]i (Figure 5D; Table 1). The response to
2-MeSADP was competitively antagonized by MRS2279 with
an afﬁnity (pKD = 8.64  0.26; Figure 5D and E) not signiﬁ-
cantly different from that for its antagonism of responses to
the P2Y1-selective ligand, MRS2365 (pKD = 8.16  0.26).
Because 2-MeSADP interacts with three P2Y receptor sub-
types, but MRS2279 binds only to P2Y1 receptors (Boyer et al.,
2002; Waldo et al., 2002; Marteau et al., 2003), these results
established that the Ca
2+ signals evoked by 2-MeSADP were
entirely mediated by P2Y1 receptors. That conclusion was
further substantiated by results with MRS2395 (30 mM) and
MRS2211 (10 mM), selective antagonists of P2Y12 and P2Y13
receptors, respectively (Xu et al., 2002; Kim et al., 2005),
neither of which affected the Ca
2+ signals evoked by any
concentration of 2-MeSADP (Figure S3). A concentration of
MRS2279 (3 mM) sufﬁcient to abolish responses to a maxi-
mally effective concentration of MRS2365 had no effect on
the Ca
2+ signals evoked by any concentration of UTP
(Figure 5F) or ATP (Figure S4). This is consistent with ATP
being only a weak partial agonist of P2Y1 receptors (Palmer
et al., 1998) and with the lack of interaction between UTP and
P2Y1 receptors (Waldo et al., 2002). We conclude that of the
three P2Y receptors expressed in ASMC that were stimulated
by 2-MeSADP (P2Y1, P2Y12 and P2Y13), only the P2Y1 recep-
tors evoke Ca
2+ signals. The peak increase in [Ca
2+]i evoked by
maximal activation of P2Y1 receptors was only 62  2% of
that evoked by ATP (Table 1).
ATP evokes Ca
2+ signals by activating P2Y2 and P2Y4 receptors
The only remaining P2Y receptors expressed in cultured
ASMC that are activated by ATP are P2Y2 and P2Y4 receptors
(Figure 1). ATP and UTP are full agonists for both rat recep-
tors, and each ligand has similar potency for each receptor
(Wildman et al., 2003). The peak amplitudes of the Ca
2+
signals evoked by ATP and UTP in ASMC were similar
(Table 1), consistent with each agonist similarly activating the
same population of receptors. UTP analogues have been used
to differentiate between human P2Y2 and P2Y4 receptors.
2′-amino-UTP and 2-thio-UTP are more selective for human
P2Y2 receptors, while 2′-azido-UTP is more selective for
human P2Y4 receptors (Jacobson et al., 2006); each analogue
is a full agonist for its respective receptor, but neither is
entirely selective. There are no antagonists that discriminate
between rat P2Y2 and P2Y4 receptors (Abbracchio et al.,
2006). Each of the three UTP analogues evoked both Ca
2+
release and Ca
2+ entry in ASMC (Figures 6A–C; Table 1). The
analogues likely to be selective for P2Y2 receptors (2′-amino-
UTP and 2-thio-UTP) evoked substantially larger Ca
2+ signals
than did the P2Y4-selective agonist (2′-azido-UTP)
(Figure 6D). We noted that the peak Ca
2+ signal evoked by
activation of both P2Y2 and P2Y4 receptors by UTP (273 
40 nM) was no larger than that evoked by activation of only
the P2Y2 receptor by 2′-amino-UTP (301  34 nM) (Table 1).
The likely explanation is that maximal responses to full ago-
nists may be limited by the ﬁnite size of the inositol 1,4,5-
trisphosphate (IP3)-sensitive Ca
2+ stores. Our results allow us
to conclude that in cultured ASMC, both P2Y2 and P2Y4
receptors evoke Ca
2+ signals, with the P2Y2 receptors contrib-
uting most to the responses evoked by ATP and UTP.
P2Y6 receptors evoke Ca
2+ signals
From the seven P2Y receptor subtypes expressed in cultured
ASMC (Figure 3A), we have so far shown that P2Y1 (Figure 5),
P2Y2 and P2Y4 receptors (Figure 6) evoke Ca
2+ signals, while
Figure 4 Ca2+ signals evoked by UTP and UDP. Concentration-
dependent effects of UDP on the peak Ca2+ signal with or without
prior treatment of the UDP with glucose and hexokinase (see text for
details) (A). These results (A) are shown as means  SEM from a single
experiment with three replicates. Concentration-dependent effects of
UTP (B) or glucose/hexokinase-treated UDP (C) on the peak increase
in [Ca
2+]i (cytosolic free Ca2+ concentration) in the presence or
absence of extracellular Ca2+, and on the sustained Ca2+ entry signal.
C denotes control.
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cal ligands of the receptors are likely to be ADP for P2Y1
receptors, and ATP or UTP for P2Y2 and P2Y4 receptors
(Abbracchio et al., 2006). The remaining subtypes of rat P2Y
receptors (P2Y6 and P2Y14) are each activated by UDP
(Nicholas et al., 1996; Fricks et al., 2008), which evokes
smaller Ca
2+ signals than either ATP or UTP in ASMC
(Figure 4A). MRS2578 has been reported to inhibit rat P2Y6
receptors selectively and irreversibly (Mamedova et al., 2004),
although it is both sparingly soluble and unstable in aqueous
solution (Abbracchio et al., 2006). In our hands, MRS2578
(10 mM) had no effect on the Ca
2+ signals evoked by any
concentration of UDP in ASMC (not shown). There are no
selective antagonists of P2Y14 receptors, although MRS2690
(Ko et al., 2007) and UDP-glucose (Chambers et al., 2000) are
selective agonists. Neither MRS2690 (10 mM) nor UDP-glucose
(10 mM) evoked Ca
2+ signals in cultured ASMC (not shown).
We attempted further to resolve the roles of P2Y6 and
P2Y14 receptors by exploiting their preferences for coupling
to different G proteins (Abbracchio et al., 2006). P2Y14 recep-
tors activate Gai/o (Moore et al., 2003), whereas P2Y6 receptors
are expected to couple to phospholipase C via Gq/11 (Chang
et al., 1995; Robaye et al., 1997). We used Pertussis toxin to
uncouple P2Y14 receptors from Gi/o and so resolve the relative
roles of P2Y6 and P2Y14 receptors in initiating the Ca
2+
signals evoked by UDP. ASMC were incubated with Pertussis
toxin (100 ng·mL
-1) for 24 h prior to examining the effects of
nucleotides on [Ca
2+]. This treatment signiﬁcantly reduced the
response to ATP: in paired comparisons, the maximal
response was reduced by 24  6% and the pEC50 shifted from
5.63  0.09 to 5.30  0.08 (Figure 7A). This is consistent with
evidence that P2Y2 receptors (via which ATP exerts its major
Ca
2+-mobilizing effect in ASMC, Figure 6) stimulate phospho-
lipase C via both Gi and Gq/11 (and/or Ga16) (Baltensperger and
Porzig, 1997; Murthy and Makhlouf, 1998). However, under
identical conditions responses to UDP were unaffected by
Pertussis toxin (Figure 7B). These results, together with the
lack of response to the P2Y14-selective agonists (MRS2690
and UDP-glucose), suggest that responses of ASMC to UDP are
mediated by P2Y6 rather than P2Y14 receptors.
Figure 5 Ca
2+ signals evoked by activation of P2Y1 receptors. Concentration-dependent effects of MRS2365 [(N)-methanocarba-2-MeSADP]
on the peak Ca
2+ signal in the presence or absence of extracellular Ca2+, and on the sustained Ca2+ entry (A). Concentration-dependent effects
of MRS2365 (B) and 2-MeSADP (2-methylthio-adenosine-5′-diphosphate) (D) on the peak Ca
2+ signal in the presence of 0–300 nM MRS2279
(2-chloro-N
6-methyl-(N)-methanocarba-2′-deoxyadenosione-3′,5′-bisphosphate) (as indicated). Results are plotted as percentages of the
maximal response in the absence of antagonist. The results from (B and D) are shown as Schild plots (C and E). Calculated afﬁnities of the
antagonist (KD) are shown. Concentration-dependent effects of UTP, alone or with MRS2279 (3 mM), on the peak Ca2+ signal (F). C denotes
control (in A, B, D and F).
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Rat (Erlinge et al., 1998) and human (Wang et al., 2002) vas-
cular smooth muscle cells express several subtypes of P2Y
receptors, but with the limited range of selective ligands avail-
able it has proven difﬁcult to resolve fully the contributions of
each to functional responses. We have shown that mRNA
encoding each of the seven rat P2Y receptor subtypes is
expressed in cultured ASMC, and a subset of these (P2Y2,
P2Y12 and P2Y14) is expressed in freshly isolated ASMC
(Figure 3). Our ﬁnding that P2Y6 predominates in cultured
cells, whereas P2Y12 is the major subtype in fresh cells, is
consistent with earlier evidence that P2Y6 receptors regulate
proliferation (Hou et al., 2002).
In cultured ASMC, ATP, UTP and UDP evoke Ca
2+ signals via
activation of phospholipase C, and each stimulates both
release of Ca
2+ from intracellular stores and Ca
2+ entry
(Figures 2C–E and 3). We have not further investigated the
identity of the Ca
2+ entry pathway, although published evi-
dence suggests that it may be via store-operated Ca
2+ entry
(Potier et al., 2009), a diacylglycerol-regulated TRP protein
(Inoue et al., 2001) or by a Na
+/Ca
2+ exchanger (Lemos et al.,
2007). By combining analyses of ligands that are either
entirely or partially subtype-selective, we have established
that four P2Y receptors evoke Ca
2+ signals and the conditions
that allow each to be activated selectively (Figure 8). P2Y1
receptors, for which ADP is the most likely physiological
stimulus, evoke Ca
2+ signals that appear to desensitize rapidly.
P2Y2 receptors, which are likely to be activated endogenously
by ATP and UTP, evoke the largest Ca
2+ signals, and these are
sustained by Ca
2+ entry during prolonged stimulation. P2Y4
receptors are also likely to be activated by ATP and UTP, but
Figure 6 Ca
2+ signals evoked by activation of P2Y2 and P2Y4 receptors. Typical results from populations of cultured ASMC stimulated with
2′-azido-UTP (100 mM, A), 2′-amino-UTP (100 mM, B) or 2-thio-UTP (100 mM, C). Results are means  SEM from three wells on a single plate
and are typical of results from three independent plates. Summary results showing concentration-dependent effects of the three analogues on
the peak Ca
2+ signal (D). C denotes control. 2′-amino-UTP, 2′-amino-2′-deoxyuridine-5′-triphosphate; 2′-azido-UTP, 2′-azido-2′-deoxyuridine-
5′-triphosphate; 2-thio-UTP, 2-thio-uridine-5′-triphosphate; ASMC, aortic smooth muscle cell; HBS, HEPES-buffered saline.
Figure 7 Ca2+ signals evoked by activation of P2Y6 receptors. Concentration-dependent effects of ATP (A) or UDP (B) on the peak Ca2+ signal
with or without pretreatment with Pertussis toxin (PTX, 100 ng·mL
-1, 24 h). Results are expressed as percentages of the peak Ca
2+ signal evoked
by a maximally effective concentration of the agonist alone. C denotes control.
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2+ signals than do P2Y2
receptors, although again the sustained phase of the response
is maintained without obvious desensitization. The relative
size of the Ca
2+ signals evoked by selective activation of P2Y2
and P2Y4 receptors is consistent with an earlier suggestion
that P2Y2 receptors mediate most of the response to UTP and
ATP (Kumari et al., 2003). In the absence of better ligands,
that conclusion derived from use of suramin as a competitive
antagonist of P2Y2 receptors (Wildman et al., 2003), but
suramin is now known to interact also with P2Y1 and P2Y6
receptors (Abbracchio et al., 2006), both of which evoke Ca
2+
signals in cultured ASMC (Figure 8). Finally, P2Y6 receptors,
for which the endogenous ligand is probably UDP, evoke Ca
2+
signals with a large sustained Ca
2+ entry phase (Figure 8). This
sustained response is consistent with the lack of desensitiza-
tion reported for human P2Y6 receptors (Robaye et al., 1997).
We also detected mRNA encoding P2Y12, P2Y13 and P2Y14
receptors in cultured ASMC (Figure 3A). Of these, P2Y14
receptors have been shown to be capable of evoking Ca
2+
signals (Fumagalli et al., 2003), but we found no evidence to
suggest that any of these P2Y receptors evokes Ca
2+ signals in
cultured ASMC (Figures 5 and 7).
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